SGLT2 Inhibitors and Electrolyte Balance
SGLT2 inhibitors cause modest but clinically favorable increases in serum magnesium and phosphate levels, without causing clinically significant imbalances in sodium, potassium, calcium, or acid-base status. These electrolyte changes represent a class effect and are generally beneficial rather than harmful. 1, 2
Magnesium Effects
SGLT2 inhibitors consistently increase serum magnesium by approximately 0.06–0.09 mmol/L compared to placebo or other glucose-lowering agents, with high-certainty evidence supporting this as a class effect. 1, 2
All four major SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ipragliflozin) demonstrate this magnesium-elevating effect, with canagliflozin showing a dose-dependent linear relationship (0.06 mmol/L at 100 mg and 0.09 mmol/L at 300 mg). 2
Dapagliflozin appears to produce the largest increment in serum magnesium (0.16 mmol/L) when compared head-to-head with other SGLT2 inhibitors, though differences between agents are not statistically significant. 1
Phosphate Effects
SGLT2 inhibitors increase serum phosphate by approximately 0.03 mmol/L (95% CI 0.02–0.04 mmol/L), representing another consistent class effect. 1
Dapagliflozin demonstrates the most robust evidence for phosphate elevation among the individual agents studied. 1
Sodium and Potassium: No Clinically Significant Changes
In both acute and chronic heart failure populations, SGLT2 inhibitors do not significantly alter serum sodium or potassium levels. 3
For acute heart failure, the weighted mean difference for sodium was 1.21 mmol/L (95% CI: -0.79 to 3.21) and for potassium was 0.11 mEq/L (95% CI: -0.20 to 0.42)—neither reaching clinical significance. 3
For chronic heart failure, sodium changed by 0.23 mmol/L (95% CI: -0.45 to 0.91) and potassium by 0.07 mEq/L (95% CI: -0.29 to 0.44)—again, not clinically meaningful. 3
SGLT2 inhibitors reduce the risk of hyperkalemia, which favorably impacts tolerance of other guideline-directed medical therapies like mineralocorticoid receptor antagonists and renin-angiotensin system inhibitors. 4
Other Electrolytes
Dapagliflozin increases plasma chloride by 1.4 mmol/L (95% CI 0.4–2.4) and plasma sulfate by 0.02 mmol/L (95% CI 0.01–0.04) compared to sulfonylurea treatment. 5
No significant changes occur in serum calcium across multiple meta-analyses of randomized controlled trials. 1, 2
Acid-Base Balance and Ketone Bodies
SGLT2 inhibitors increase urinary excretion of ketone bodies (acetoacetate by 48 μmol/day and β-hydroxybutyrate by 59 μmol/day) and citrate (by 0.93 mmol/day) without disturbing acid-base balance. 5
The increase in urinary citrate excretion may reflect beneficial effects on cellular metabolism, including the tricarboxylic acid cycle, potentially contributing to kidney protection. 5
Despite concerns about diabetic ketoacidosis, no consistent increase in acid-base disturbances has been observed in major clinical trials. 6
Electrocardiographic Safety
No differences in QT interval prolongation, PR interval changes, ST-T abnormalities, bundle branch blocks, or ventricular arrhythmias were observed between SGLT2 inhibitor users and non-users in a large multi-center study. 7
This electrocardiographic safety profile confirms that the modest electrolyte changes induced by SGLT2 inhibitors do not translate into cardiac conduction abnormalities. 7
Clinical Implications
The electrolyte effects of SGLT2 inhibitors are favorable rather than harmful, with magnesium and phosphate increases potentially contributing to cardiovascular and renal protection. 1, 2
Do not withhold SGLT2 inhibitors due to concerns about electrolyte imbalances—the safety profile is robust across diverse populations including those with chronic kidney disease and heart failure. 4, 6
SGLT2 inhibitors improve tolerance of other heart failure therapies by reducing hyperkalemia risk and slowing kidney function decline, making them foundational agents in treatment sequencing. 4